Dupilumab in patients with diffuse type 2 CRSwNP had beneficial changes in nasal passage microbiota but did not alter gastrointestinal microbiota.

Dupilumab in combination with other biologic agents is safe and effective for treating various chronic inflammatory conditions.

The global Biosimilars Market , valued at US$32.75 billion in 2024 stood at US$35.04 billion in 2025 and is projected to ...

A major international study led by researchers at McMaster University has identified the most effective and safest treatments for people living with chronic hives, also known as chronic urticaria.